Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NABOTA vs BOTOX in Essential Blepharospasm
NCT02947815Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2016
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prabotulinumtoxinA in benign essential blepharospasm (BEB) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Change from baseline in Scott's Scale Score at 4 weeks. Started Oct 2016; status: completed.
02
Drugs
prabotulinumtoxinA
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT02947815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947815.